Table 2.

Quality control of CHD case and MFHS control cohorts and genotyping data

	Subjects, n		Subjects, n
MFHS Control Cohort		CHD Case Cohort
Starting subjects	950	Starting subjects	1,020
Remaining subjects	880	Remaining subjects	958
QC Exclusions	% Total		% Total
MAPD QC	3.05	MAPD QC	2.35
Segment QC	4.32	Segment QC	2.15
Consent QC	NA	Consent QC	0.10
Sex QC	NA	Sex QC	0.59

Copy number analysis exclusions were as follows: median absolute pairwise difference (MAPD) quality control (QC) ≥0.35, number of copy number polymorphism (CNP) segments ≥250, 1 subject with a status change to his/her consent, and sex tracking QC. Congenital heart disease (CHD) cases were reduced to a final n = 945 after inclusion and exclusion criteria were met.